Frontlight ResearchEarly access
Pancreatic cancer trials in China
326 trials · From ClinicalTrials.gov, checked 16 November 2026. Ask the study team whether a trial fits you.
- Phase 3Not yet taking people in ChinaA Study of FG-M108+Chemotherapy vs Placebo+Chemotherapy in Claudin18.2-positive Pancreatic Cancer
- Where
- Shanghai
- Age
- 18 years to 80 years
- People
- 524
- Run by
- FutureGen Biopharmaceutical (Beijing) Co., Ltd
See details and how to joinNCT07383922 - Phase 2Enrolling by invitationNimotuzumab Combined With Chemoradiotherapy in the Treatment of Unresectable Locally Advanced or Oligometastatic Pancreatic Cancer
- Where
- Beijing
- Age
- 18 years to 80 years
- People
- 30
- Run by
- Peking University First Hospital
See details and how to joinNCT07386704 - Phase 2Taking peopleQL1706 Plus Chidamide, AG as First-line Treatment for Metastatic Pancreatic Cancer
- Where
- Tianjin
- Age
- 18 years to 75 years
- People
- 33
- Run by
- Tianjin Medical University Cancer Institute and Hospital
See details and how to joinNCT06951997 - Phase 1/2Taking peopleLDRT Combined With Pucotenlimab and Standard Therapy for Advanced Pancreatic Cancer: A Single-Arm Study
- Where
- Hangzhou
- Age
- 18 years to 75 years
- People
- 10
- Run by
- Zhejiang Provincial People's Hospital
See details and how to joinNCT07312422 - Phase 1Taking peopleStudy of CEA Targeting CAR-T (PTC13) in the Treatment of CEA-Positive Advanced Malignant Solid Tumors
- Where
- Hangzhou
- Age
- 18 years and over
- People
- 18
- Run by
- Weijia Fang, MD
See details and how to joinNCT06821048 - No phaseTaking peopleLaryngopharyngeal Injury After Endotracheal Intubation Under General Anesthesia
- Where
- Hangzhou
- People
- 1,200
- Run by
- Zhejiang University
See details and how to joinNCT07359586 - Phase 1/2Taking peopleA Phase I/IIa Study of JAB-23E73 in Patients With Advanced Solid Tumors Harboring KRAS Gene Alteration
- Where
- Beijing, Changsha, Chengdu, Fuzhou, Guangzhou, Haerbin, Hangzhou, Hefei, Langfang, Nanchang, Nanjing, Nanning, Shanghai, Shenyang, Suzhou, Taiyuan, Tianjin, Wuhan, Xi’an, Zhengzhou
- People
- 334
- Run by
- Jacobio Pharmaceuticals Co., Ltd.
See details and how to joinNCT06959615 - No phaseTaking people68Ga-PFA2 PET Imaging for the Diagnosis of Annexin A2-Positive Tumors
- Where
- Beijing
- Age
- 18 years to 80 years
- People
- 10
- Run by
- Peking University First Hospital
See details and how to joinNCT07331532 - Phase 1/2Taking peopleHRS-4642 Combination With Other Antitumor Therapies in Patients With Solid Tumors
- Where
- Beijing
- Age
- 18 years to 75 years
- People
- 60
- Run by
- Shanghai Hengrui Pharmaceutical Co., Ltd.
See details and how to joinNCT07296341 - Phase 1Taking peopleA Phase I Clinical Study of IX001 TCR-T Injection in the Treatment of Advanced Pancreatic Cancer Patients With KRAS G12V Mutation
- Where
- Guangzhou
- Age
- 18 years to 75 years
- People
- 9
- Run by
- Sun Yat-sen University
See details and how to joinNCT06898385 - No phaseTaking peopleTreatment of Irinotecan Hydrochloride Liposome Injection II in China: a Real World Study of Pancreatic Cancer Patients
- Where
- Beijing, Hefei, Henan, Nanning, Ningbo, Shanghai, Wuhan, Zhengzhou
- Age
- 18 years to 100 years
- People
- 3,000
- Run by
- Peking Union Medical College Hospital
See details and how to joinNCT06375473 - Phase 2Taking peopleExploratory Platform Research on Precision Therapy of Advanced Pancreatic Cancer
- Where
- Shanghai
- Age
- 18 years to 75 years
- People
- 160
- Run by
- Fudan University
See details and how to joinNCT06547736 - Phase 2Taking peopleQL1706+Lenvatinib+AG Regimen as First-line Treatment for Advanced Metastatic Pancreatic Cancer
- Where
- Nanjing
- Age
- 18 years and over
- People
- 80
- Run by
- Du Juan
See details and how to joinNCT07110064 - No phaseTaking peopleTarget-specific immunoPET Imaging of Digestive System Carcinoma
- Where
- Shanghai
- Age
- 18 years to 75 years
- People
- 400
- Run by
- RenJi Hospital
See details and how to joinNCT06715839 - No phaseTaking peopleImmunoPET Imaging of Pancreatic Cancer
- Where
- Shanghai
- Age
- 18 years to 70 years
- People
- 90
- Run by
- RenJi Hospital
See details and how to joinNCT06602037 - Phase 2Taking peopleIRE Combined With the Dual-Function Antibody PD-1/CTLA-4 for the Treatment of LAPC Following Failure of First-Line AG Therapy
- Where
- Shanghai
- Age
- 18 years and over
- People
- 20
- Run by
- Ruijin Hospital
See details and how to joinNCT07306273 - Phase 2Taking peopleCryoablation Combined With the Dual-Function Antibody PD-1/CTLA-4 for the Treatment of LAPC Following Failure of First-Line AG Therapy
- Where
- Shanghai
- Age
- 18 years and over
- People
- 20
- Run by
- Ruijin Hospital
See details and how to joinNCT07306286 - Phase 1/2Taking peopleMutant KRAS G12V-specific TCR Transduced T Cell Therapy for Advanced Pancreatic Cancer
- Where
- Shanghai
- Age
- 18 years to 75 years
- People
- 30
- Run by
- Changhai Hospital
See details and how to joinNCT04146298 - No phaseTaking peopleClinical Application of PET Imaging Targeting CLDN18.2 in Malignant Tumors
- Where
- Wuhan
- Age
- 18 years and over
- People
- 56
- Run by
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
See details and how to joinNCT07301814 - No phaseTaking peopleWhether Control of Serum Uric Acid (SUA) Improves Survival After Pancreatic Cancer
- Where
- Lanzhou
- Age
- 18 years to 85 years
- People
- 168
- Run by
- Hepatopancreatobiliary Surgery Institute of Gansu Province
See details and how to joinNCT07091526 - Phase 3Not yet taking people in ChinaActive Anti-diabetic Treatment Plus Chemotherapy for Pancreatic Cancer Related Diabetes
- Where
- Shanghai
- Age
- 18 years to 80 years
- People
- 210
- Run by
- Fudan University
See details and how to joinNCT07272109 - Early phase 1Taking peopleA Study of GC101 TIL in Advanced Hepatobiliary-Pancreatic Cancers (10hospital)
- Where
- Shanghai
- Age
- 18 years to 75 years
- People
- 50
- Run by
- Shanghai Juncell Therapeutics
See details and how to joinNCT05098197 - Phase 2Not yet taking people in ChinaNimotuzumab Combined With Nab-paclitaxel/Gemcitabine in the Perioperative Treatment of High-risk Resectable/Borderline Resectable Pancreatic Cancer
- Where
- Beijing, Nanjing
- Age
- 18 years to 75 years
- People
- 156
- Run by
- The First Affiliated Hospital with Nanjing Medical University
See details and how to joinNCT07277452 - Phase 3Taking peopleIrinotecan Hydrochloride Liposome Injection (II)in Combination With Oxaliplatin, 5-FU/LV Versus AG for First-line Treatment of Metastatic Pancreatic Cancer
- Where
- Beijing
- Age
- 18 years to 75 years
- People
- 662
- Run by
- Jiangsu HengRui Medicine Co., Ltd.
See details and how to joinNCT07238283 - Phase 2Taking peopleAdebrelimab and Chidamide for Pancreatic Cancer
- Where
- Nanjing
- Age
- 18 years to 75 years
- People
- 45
- Run by
- Liu Xiufeng
See details and how to joinNCT06584227